Neoadjuvant immunotherapy of locoregionally advanced solid tumors.

ABSTRACT: Definitive management of locoregionally advanced solid tumors presents a major challenge and often consists of a combination of surgical, radiotherapeutic and systemic therapy approaches. Upfront surgical treatment with or without adjuvant radiotherapy carries the risks of significant morbidities and potential complications that could be lasting. In addition, these patients continue to have a high risk of local or distant disease relapse despite the use of standard adjuvant therapy. Preoperative neoadjuvant systemic therapy has the potential to significantly improve clinical outcomes, particularly in this era of expanding immunotherapeutic agents that have transformed the care of patients with metastatic/unresectable malignancies. Tremendous progress has been made with neoadjuvant immunoth

SUBMITTER: Tarhini AA 

PROVIDER: S-EPMC9386211 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature